Loading the records…
Rob Bresnahan
RepublicanPA08•house•Filed Jun 9, 2025
View all of Rob Bresnahan's trades →23 total filings on record
Rob Bresnahan (R-PA) bought $1K-$15K of $ABBV (AbbVie Inc. Common Stock (ABBV)) on May 15, 2025, part of 54 transactions in this filing (28 buys, 26 sells).
Transactions
54
Companies
50
Largest Trade
$1K-$15K
Timing Flags
None
Price Movement Since Trade
How the largest positions have moved from the trade date to the most recent close.
$ABBV✓ GOOD CALL
Health Care
Trade Day
$181.68
May 15, 2025
Current
$198.69
Apr 24, 2026
Change
+9.36%
+$17.01
Materials
Real Estate
$BAX✗ LOSING
Trade Day
$31.04
May 15, 2025
Current
$18.16
Apr 24, 2026
Change
-41.49%
$-12.88
Health Care
Showing the 6 largest positions. See every transaction in the table below.
🔒
Sign Up to See More
See the full trade breakdown, suspicious timing flags, and how this filing connects to active legislation.
Get Free Access →Share This Filing
All Transactions
| Type | Ticker | Asset | Amount | Trade Price | Current | Change | Date |
|---|---|---|---|---|---|---|---|
| BUY | $ABBV | AbbVie Inc. Common Stock (ABBV) | $1K-$15K | $181.68 | $198.69 | +9.4% | May 15, 2025 |
| BUY | $APD | Air Products and Chemicals, Inc. Common Stock (APD) | $1K-$15K | $274.42 | — | — | May 15, 2025 |
| BUY | $BAX | Baxter International Inc. Common Stock (BAX) | $1K-$15K | $31.04 | $18.16 | -41.5% | May 15, 2025 |
| BUY | $BDX | Becton, Dickinson and Company Common Stock (BDX) | $1K-$15K | $135.43 | — | — | May 15, 2025 |
| BUY | $BIIB | Biogen Inc. - Common Stock (BIIB) | $1K-$15K | $123.70 | — | — | May 15, 2025 |
| BUY | $DXCM | DexCom, Inc. - Common Stock (DXCM) | $1K-$15K | $85.67 | — | — | May 15, 2025 |
| BUY | $DOW | Dow Inc. Common Stock (DOW) | $1K-$15K | $29.90 | — | — | May 15, 2025 |
| BUY | $EOG | EOG Resources, Inc. Common Stock (EOG) | $1K-$15K | — | — | — | May 15, 2025 |
| BUY | $IDXX | IDEXX Laboratories, Inc. - Common Stock (IDXX) | $1K-$15K | $511.99 | — | — | May 15, 2025 |
| BUY | $JPM | JP Morgan Chase & Co. Common Stock (JPM) | $1K-$15K | $267.49 | — | — | May 15, 2025 |
BUY$1K-$15K
$APDAir Products and Chemicals, Inc. Common Stock (APD)
$274.42 \u2192 N/A
May 15, 2025 \u2022 self
BUY$1K-$15K
$BAXBaxter International Inc. Common Stock (BAX)
$31.04 \u2192 $18.16-41.5%
May 15, 2025 \u2022 self
BUY$1K-$15K
$BDXBecton, Dickinson and Company Common Stock (BDX)
$135.43 \u2192 N/A
May 15, 2025 \u2022 self
BUY$1K-$15K
$IDXXIDEXX Laboratories, Inc. - Common Stock (IDXX)
$511.99 \u2192 N/A
May 15, 2025 \u2022 self
Connected Legislative Activity
10 signalsThese bills and contracts share tickers or sectors with this filing's trades.
BillS1885bearish
Stop the Scroll Act
The Stop the Scroll Act (S.1885) is a bearish catalyst for ad-revenue-dependent social media platforms. Despite recent rallies, this bill mandates FTC/Surgeon General warning labels on platforms like those owned by META, SNAP, and PINS. Real market data shows META dropped -10.36% in the past 7 days, while SNAP and PINS remain off their 52-week highs, indicating market sensitivity to regulatory risk.
Apr 14, 2026
METAPINSSNAP
BillHR3491neutral
DeOndra Dixon INCLUDE Project Act of 2025
HR3491 (DeOndra Dixon INCLUDE Project Act) authorizes a Down syndrome research program at NIH but appropriates zero funding. With only 5 procedural actions over a year and stalled committee markup, the bill has no near-term market impact. No public companies are directly affected.
May 21, 2026
BillS1816neutral
Improving Seniors’ Timely Access to Care Act of 2025
The Improving Seniors' Timely Access to Care Act mandates electronic prior authorization for all Medicare Advantage plans by 2028, forcing a regulatory-driven health IT spending wave. Oracle (ORCL) is the clearest beneficiary as dominant EHR vendor, while major MA insurers (UNH, ELV, HUM, CVS) face mandated IT investment but gain long-term operational efficiency. The bill has strong bipartisan momentum with 68 cosponsors and an identical House companion.
May 20, 2025
CVSELVHUMORCLUNH
BillHR3731bullish
Small Biotech Innovation Act
The Small Biotech Innovation Act (HR3731) is an early-stage bill that would exempt R&D-intensive small biotech manufacturers (≤5 qualifying drugs) from Medicare drug price negotiations starting in 2029. The bill is in committee with no floor action, and no market reaction is evident from provided data. The legislative path is long and uncertain — this is a structural watch item, not a trading catalyst.
Jun 4, 2025
BIIBMRNAREGN
BillS1847bearish
Association Health Plans Act
S.1847 is an early-stage bill expanding self-funded association health plans for small businesses, structurally negative for fully insured commercial carriers. The bill has no dollar authorization and remains in committee with only 6 sponsors — near-term passage probability is low. Real market data shows large health insurers (UNH, HUM, CVS, CNC) surging 15-55% in the last 30 days, but this rally is unrelated to S.1847 and driven by broader sector dynamics.
May 21, 2025
CNCCVSMOH
BillHR67bullish
Modernizing Retrospective Regulatory Review
HR67 mandates federal agencies adopt AI-driven regulatory review tools, creating a new procurement category that benefits established FedRAMP-authorized cloud providers. The bill is pure authorization with no direct appropriations, but structural adoption requirements generate recurring revenue for $ORCL, $IBM, and $MSFT. Partner AI providers (e.g., Palantir, C3.ai) are secondary beneficiaries with lower confidence.
May 21, 2025
IBMMSFTORCL
BillS1918neutral
Access Technology Affordability Act of 2025
S. 1918 is an early-stage, low-probability bill proposing a refundable tax credit for blind individuals purchasing access technology. It creates no direct revenue stream for any public company and has negligible near-term market impact.
May 22, 2025
BillS1875neutral
Streamlining Federal Cybersecurity Regulations Act of 2025
S.1875 is an early-stage procedural bill to create an interagency committee for harmonizing federal cybersecurity regulations. It contains no funding, no mandates, and no procurement directives. Near-term market impact is negligible.
May 22, 2025
CRWDPANW
BillHR3565bearish
To provide for a limitation on the transfer of defense articles and defense services to Israel.
HR3565, a bill restricting the transfer of specific bombs and artillery ammunition to Israel, is in early legislative stages but introduces headline risk for defense primes with Israeli exposure. Actual market data shows LMT down 15.87% over 30 days, RTX down 9.55%, and defense stocks broadly under pressure, though this is only one factor among many. The bill faces an uphill path through committee and full chambers, but the restriction mechanism is specific and actionable.
May 21, 2025
BAGDLMTNOCRTX
BillS1929bullish
SEPSIS Act
The SEPSIS Act (S.1929) is an early-stage authorization bill that would create federal programs for sepsis research, education, and data collection. It authorizes but does not appropriate funding, and with only 6 cosponsors and referral to committee in June 2025, passage remains uncertain. Real market data shows all four diagnostic/lab stocks have declined 1-6% in the past week and 2-10% over 30 days, reflecting broader market pressure on healthcare despite the legislative catalyst.
Jun 3, 2025
BDXTMO
Other Filings by Rob Bresnahan
Free — no credit card
Get the next Bresnahan trade the day it's disclosed
HillSignal tracks every Congressional stock filing and federal contract, scores its market impact with AI, and emails you the ones that matter — before they hit the news.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.